Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 1 2Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

NIH 13OTHER 9INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

NSCLC 1Advanced Solid Tumor 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × tipifarnib × Clear all
NCT04865159 2023-09-21

Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Kura Oncology, Inc.

Phase 1 Terminated
6 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡